Additional Proxy Soliciting Materials (definitive) (defa14a)
June 01 2021 - 9:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the
Securities Exchange Act of 1934
Filed by the Registrant ☒ Filed
by a Party other than the Registrant ☐
Check the appropriate box:
☐
|
Preliminary Proxy Statement
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☐
|
Definitive Proxy Statement
|
☐
|
Definitive Additional Materials
|
☒
|
Soliciting Material under Rule 14a-12
|
SCOPUS BIOPHARMA INC.
(Exact Name of Registrant as Specified in
Its Charter)
Payment of Filing Fee (Check the appropriate box):
☒
|
No fee required.
|
☐
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
|
|
(1) Title
of each class of securities to which transaction applies:
|
|
(2) Aggregate
number of securities to which transaction applies:
|
|
(3) Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing
fee is calculated and state how it was determined):
|
|
(4) Proposed
maximum aggregate value of transaction:
|
|
|
☐
|
Fee paid previously with preliminary materials.
|
☐
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
(1) Amount
previously paid:
|
|
(2) Form,
Schedule or Registration Statement No.:
|
|
|
|
|
Scopus BioPharma Announces New Date for 2021
Annual Meeting of Stockholders
New York, New York, May 31, 2021 – Scopus
BioPharma Inc. (Nasdaq: “SCPS”) today announced that the board of directors has rescheduled the company’s
2021 Annual Meeting of Stockholders (“2021 Annual Meeting”), which will be held on October 8, 2021.
Pursuant to the company’s By-laws, in order
for stockholder proposals of business and director nominations (including director nominations under the company’s proxy access
by-law) to be presented at the 2021 Annual Meeting (other than by means of inclusion in the company’s proxy materials under Rule
14a-8 as described below), notice must delivered to our secretary at the company’s principal executive offices (420 Lexington Avenue,
Suite 1402, New York, New York 10170) no later than June 10, 2021, which is 10 days after public disclosure of the date of the 2021 Annual
Meeting. In addition, stockholder proposals intended for inclusion in the company’s proxy statement for the 2021 Annual Meeting
pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended, must be delivered to the secretary at the company’s
principal executive offices (at the address provided above) no later than June 25, 2021 (which the company believes is a reasonable time
before the company begins to print and send its proxy materials).
About Scopus BioPharma
Scopus BioPharma Inc. is a biopharmaceutical
company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research
and academic institutions. The company’s lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment
of multiple cancers. This drug candidate is highly distinctive, encompassing both RNA therapy and immunotherapy by synthetically linking
siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune
activation in the tumor microenvironment. The company is also developing additional new chemical entities to treat other serious diseases
with significant unmet medical needs, including systemic sclerosis. Receive updates by following Scopus BioPharma on Twitter here.
Forward-Looking Statements
This press release may include forward-looking
statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking
statements are subject to risks (including those set forth in the company’s Form 10-K for the fiscal year ended December 31, 2020,
as amended, filed with the U.S. Securities and Exchange Commission (“SEC”)) and uncertainties which could cause actual results
to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with
respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if
our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize,
actual results could vary materially from our expectations and projections.
Important Additional Information and Where
to Find It
Scopus Biopharma Inc. plans to file a proxy statement
(the “Proxy Statement”) with the SEC in connection with the solicitation of proxies for the 2021 Annual Meeting, together
with a WHITE proxy card. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY
OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY
WILL CONTAIN IMPORTANT INFORMATION.
Stockholders will be able to obtain, free of charge,
copies of the Proxy Statement, any amendments or supplements thereto and any other documents (including the WHITE proxy card) when filed
by the company with the SEC in connection with the 2021 Annual Meeting at the SEC’s website (https://www.sec.gov), at the company’s
website (https://scopusbiopharma.com) or by contacting the company’s proxy solicitor, Morrow Sodali, at (203) 658-9400 or, by e-mail,
at SCPS@investor.morrowsodali.com.
Participants in the Solicitation
The company, its directors and certain of its
executive officers and other employees may be deemed to be participants in the solicitation of proxies from stockholders in connection
with the 2021 Annual Meeting. Additional information regarding the identity of these potential participants, none of whom (other than
Ira Scott Greenspan, Joshua R. Lamstein, Paul E. Hopper, Ashish P. Sanghrajka and Robert J. Gibson) owns in excess of one percent (1%)
of the company’s voting shares, and their direct or indirect interests, by security holdings or otherwise, will be set forth in
the Proxy Statement and other materials to be filed with the SEC in connection with the 2021 Annual Meeting. Information relating to the
foregoing can also be found in the company’s Form 10-K/A, filed with the SEC on April 29, 2021. To the extent holdings of the company’s
securities by such potential participants (or the identity of such participants) have changed since the information printed in the Form
10-K/A, such information has been or will be reflected on Statements of Change in Ownership on Forms 3 and 4 filed with the SEC. You may
obtain free copies of these documents using the sources indicated above.
Contacts
Rodd Leeds/David Waldman
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: SCPS@crescendo-ir.com
Hugh Burns/Delia Cannan/Nicholas Leasure
Reevemark
Tel: (212) 433-4600
Email: scopus@reevemark.com
Stockholder Contact
Mike Verrechia/Bill Dooley
Morrow Sodali, LLC
Tel: (203) 658-9400
Email: SCPS@investor.morrowsodali.com
Scopus BioPharma (NASDAQ:SCPS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scopus BioPharma (NASDAQ:SCPS)
Historical Stock Chart
From Jul 2023 to Jul 2024